IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

(marketscreener.com) - Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer- Starting dose of IDE161 in the Phase 1 dose escalation is one-half of the projected human efficacious dose, based on preclinical studies- IDE161 monotherapy clinical...https://www.marketscreener.com/quote/stock/IDEAYA-BIOSCIENCES-INC-58457878/news/IDEAYA-Announces-IND-Clearance-by-U-S-FDA-enabling-Phase-1-Initiation-for-First-in-Class-PARG-Devel-42690508/?utm_medium=RSS&utm_content=20230109